<DOC>
	<DOCNO>NCT01473043</DOCNO>
	<brief_summary>This single arm study axitinib patient advanced kidney cancer ( clear cell variant ) , fail first line therapy . The study recruit maximum 30 patient 2 country include Australia Canada . Patients follow efficacy , safety health relate outcome .</brief_summary>
	<brief_title>Clinical Study With Axitinib In Advanced Kidney Cancer , Who Have Failed First Line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Metastatic renal cell carcinoma component clear cell subtype . Prior first line systemic therapy At least 1 measurable lesion per Response Evaluation Criterion Solid Tumors [ RECIST 1.1 ] . Adequate hematology , liver kidney function Eastern Cooperative Oncology Group [ ECOG ] performance status 0 1 . Life expectancy â‰¥12 week . Normotensive well control hypertension ( less than/equal 140/90 mm Hg . ) Negative pregnancy test Adequate recovery time prior systemic therapy , surgery radiation Willing able subject sign consent More one prior systemic therapy regimen Major bowelpenetrating surgery &lt; 4 week Active gastro intestinal bleed past 3 month Active peptic ulcer disease past 6 month Current anticipate use potent CYP3A4/5 inhibitor Current anticipate use know CYP3A4/5 CYP1A2 inducer Requirement therapeutic warfarin high dose steroid Symptomatic untreated brain metastasis A serious uncontrolled medical disorder active infection Pregnant breastfeeding female History another active malignancy Dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Axitinib</keyword>
	<keyword>metastatic renal cell carcinoma</keyword>
</DOC>